Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

“Obviously what the ISAR-REACT 5 trial showed was the importance of comparing the two medications head-to-head, and based on that trial the European guidelines recommended that for non-ST elevation ACS prasugrel should be considered in preference to ticagrelor in patients who are proceeding to PCI. This study reiterates that point and highlights that these are the patients that perhaps benefit from this prasugrel-based strategy.”